¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå
Fluorescence Guided Surgery Systems
»óǰÄÚµå : 1780820
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 370 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 4¾ï 5,490¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 860¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀåÀº 2030³â¿¡´Â 4¾ï 5,490¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 13.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ SPY ½Ã½ºÅÛÀº CAGR 13.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 970¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. PDE ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 13.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5,680¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 18.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡´Â 5,680¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 9,630¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 18.4%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 10.3%¿Í 12.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 11.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çü±¤ À¯µµ ¼ö¼úÀÌ Á¾¾çÇÐ ¹× ½Å°æ¿Ü°ú ºÐ¾ßÀÇ °ÔÀÓ Ã¼ÀÎÀú°¡ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Çü±¤ À¯µµ ¼ö¼ú(Fluorescence Guided Surgery, FGS)Àº Çü±¤Áõ¹éÁ¦¸¦ ÀÌ¿ëÇØ Á¾¾çÀ̳ª ¸²ÇÁÀý, Áß¿ä Á¶Á÷À» ½Ç½Ã°£À¸·Î °¡½ÃÈ­ÇÏ¿© ¼ö¼úÀÇ Á¤È®¼º¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº Á¾¾çÇÐ, ½Å°æ¿Ü°ú, ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡¼­ ƯÈ÷ °¡Ä¡°¡ ÀÖÀ¸¸ç, ¿ÏÀü ÀýÁ¦¸¦ À§Çؼ­´Â Á¤È®ÇÑ Á¾¾ç ¸¶Áø °ËÃâÀÌ ÇʼöÀûÀÔ´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ¾Ï Ä¡·áÀÇ Ã¤Åà Áõ°¡¿Í °íÇü¾ÏÀÇ À¯º´·ü Áõ°¡°¡ FGS ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÙÀû¿Ü¼±(NIR) À̹Ì¡°ú Ç¥Àû Çü±¤ Á¶¿µÁ¦ÀÇ ¹ßÀüÀº ¼ö¼úÀÇ Á¤È®µµ¸¦ ³ôÀ̰í Àç¹ß·üÀ» ³·Ã߸ç ȯÀÚÀÇ »ýÁ¸À²À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á°¡ ´ëÁßÈ­µÊ¿¡ µû¶ó Çü±¤ À¯µµ ¼ö¼úÀº º¹ÀâÇÑ ¼ö¼úÀÇ Ç¥ÁØÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú ¹ßÀüÀÌ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛÀ» Çâ»ó½Ã۰í Àִ°¡?

ºÐÀÚ À̹Ì¡, AI¸¦ Ȱ¿ëÇÑ Çü±¤ ¸ÅÇÎ, »ýüÀûÇÕ¼º Á¶¿µÁ¦ÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î FGS ½Ã½ºÅÛÀÇ À¯È¿¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¾Ï Á¶Á÷¿¡ ¼±ÅÃÀûÀ¸·Î °áÇÕÇϴ ǥÀû Çü±¤ ÇÁ·ÎºêÀÇ °³¹ß·Î Á¾¾çÀÇ °¡½Ã¼ºÀÌ Çâ»óµÇ°í °Ç°­ÇÑ ±¸Á¶¿¡ ´ëÇÑ ¼Õ»óÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ À̹Ì¡ ¼ÒÇÁÆ®¿þ¾î´Â ½Ç½Ã°£ Á¶Á÷ °¨º°À» °¡´ÉÇÏ°Ô Çϰí, ¼ö¼ú Áß ¿Ü°úÀǻ縦 º¸´Ù È¿°úÀûÀ¸·Î À¯µµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Çü±¤°ú MRI ¹× PET ½ºÄµ°ú °°Àº ´Ù¸¥ ¿µ»ó ¾ç½ÄÀ» °áÇÕÇÑ ÇÏÀ̺긮µå ¿µ»ó ½Ã½ºÅÛÀº ´õ ³ªÀº ¼ö¼úÀû ÀÇ»ç°áÁ¤À» À§ÇÑ ´ÙÃþÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ·Îº¿ º¸Á¶ Çü±¤ À¯µµ ¼ö¼úÀÇ ÅëÇÕÀº º¹ÀâÇÑ ¼ö¼úÀÇ Á¤È®µµ¸¦ ´õ¿í ³ôÀ̰í ħ½ÀÀ» ÁÙÀÔ´Ï´Ù.

±ÔÁ¦¿Í ½ÃÀå µ¿ÇâÀº Çü±¤ À¯µµ ¼ö¼ú¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

FDA ¹× EMA¿Í °°Àº ±ÔÁ¦±â°üÀº Çü±¤ Á¶¿µÁ¦ ¹× ¿µ»ó ½Ã½ºÅÛÀÇ ½ÂÀÎÀ» °¨µ¶ÇÏ°í ±× ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ¼ö¼ú Áß ¿µ»ó°ú Á¤¹Ð Á¾¾çÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¾Ï Ä¡·á ÇÁ·ÎÅäÄÝ¿¡¼­ FGSÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â º´¿øµéÀÌ Ã·´Ü Çü±¤ À¯µµ º¹°­°æ ¼ö¼ú ½Ã½ºÅÛ ¹× ·Îº¿ ¼ö¼ú ½Ã½ºÅÛ¿¡ ÅõÀÚÇÏ´Â °ÍÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. AI Áö¿ø ¼ö¼ú °èȹ ÅøÀÇ È®´ëµµ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ¼ö¼ú Àü Á¾¾ç ¹× Ç÷°ü ±¸Á¶ÀÇ ´õ ³ªÀº ¸ÅÇÎÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¼ö¼ú ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó Çü±¤ À¯µµÇÏ ¼ö¼úÀº ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀå µ¿·ÂÀº?

FGSÀÇ ¹Ì·¡´Â AI¸¦ Ȱ¿ëÇÑ ¿µ»ó ºÐ¼®, Â÷¼¼´ë Çü±¤ Á¶¿µÁ¦, ·Îº¿ º¸Á¶ ¼ö¼ú Ç÷§ÆûÀÇ Ã¤Åà Ȯ´ë·Î Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ƯÁ¤ ¾ÏÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ºÐÀÚ À̹Ì¡ ¿°·áÀÇ °³¹ß·Î Á¾¾çÀÇ À§Ä¡ ÆÄ¾Ç°ú ¼ö¼úÀÇ Á¤È®µµ¸¦ ´õ¿í Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ÀÇ»ç°áÁ¤ Áö¿ø ÅøÀº ½Ç½Ã°£ ¼ö¼ú Áß °¡ÀÌ´ø½º¸¦ °­È­Çϰí, ¼ö¼ú ½Ç¼ö¸¦ ÁÙÀ̸ç, ÀýÁ¦¼úÀÇ ¿ÏÀü¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°Ý ¼ö¼ú°ú ¿ø°Ý ·Îº¿ ¼ö¼úÀÇ Àû¿ëÀÌ È®´ëµÇ¸é ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­µµ FGS¸¦ ´õ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù. Á¤¹Ð ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Çü±¤ À¯µµ ¼ö¼úÀº Çö´ëÀÇ ¿Ü°ú Á¾¾çÇÐ ¹× ½Å°æ¿Ü°ú¸¦ °è¼Ó ÀçÁ¤ÀÇÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

À¯Çü(SPY ½Ã½ºÅÛ, PDE ½Ã½ºÅÛ, VS3 À̸®µã ½Ã½ºÅÛ, ±âŸ), ¼ö¼ú(°üÇ÷Àû ¼ö¼ú, º¹°­°æ/³»½Ã°æ ¼ö¼ú), ¾ÖÇø®ÄÉÀ̼Ç(¾Ï¼ö¼ú, ½ÉÀåÇ÷°ü ¿Ü°ú, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Fluorescence Guided Surgery Systems Market to Reach US$454.9 Million by 2030

The global market for Fluorescence Guided Surgery Systems estimated at US$208.6 Million in the year 2024, is expected to reach US$454.9 Million by 2030, growing at a CAGR of 13.9% over the analysis period 2024-2030. SPY Systems, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$209.7 Million by the end of the analysis period. Growth in the PDE Systems segment is estimated at 13.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$56.8 Million While China is Forecast to Grow at 18.4% CAGR

The Fluorescence Guided Surgery Systems market in the U.S. is estimated at US$56.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$96.3 Million by the year 2030 trailing a CAGR of 18.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.3% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.0% CAGR.

Global Fluorescence Guided Surgery Systems Market - Key Trends & Drivers Summarized

Why Is Fluorescence Guided Surgery Becoming a Game-Changer in Oncology and Neurosurgery?

Fluorescence guided surgery (FGS) is revolutionizing surgical precision by enabling real-time visualization of tumors, lymph nodes, and critical tissues using fluorescent dyes. This technique is particularly valuable in oncology, neurosurgery, and minimally invasive procedures, where precise tumor margin detection is essential for complete resection. The growing adoption of personalized cancer treatment and the increasing prevalence of solid tumors are driving demand for FGS systems. Additionally, advancements in near-infrared (NIR) imaging and targeted fluorescence contrast agents are enhancing surgical accuracy, reducing recurrence rates, and improving patient survival. As precision medicine gains traction, fluorescence guided surgery is becoming a standard in complex surgical interventions.

What Technological Advancements Are Improving Fluorescence Guided Surgery Systems?

Breakthroughs in molecular imaging, AI-powered fluorescence mapping, and biocompatible contrast agents are enhancing the efficacy of FGS systems. The development of targeted fluorescent probes that bind selectively to cancerous tissues is improving tumor visibility and reducing damage to healthy structures. AI-driven imaging software is enabling real-time tissue differentiation, guiding surgeons more effectively during procedures. Additionally, hybrid imaging systems combining fluorescence with other imaging modalities, such as MRI and PET scans, are providing multi-layered insights for better surgical decision-making. The integration of robotic-assisted fluorescence guided surgery is further enhancing precision and reducing invasiveness in complex operations.

How Are Regulations and Market Trends Influencing Fluorescence Guided Surgery?

Regulatory agencies such as the FDA and EMA oversee the approval of fluorescence contrast agents and imaging systems, ensuring their safety and effectiveness. The increasing emphasis on intraoperative imaging and precision oncology is driving the adoption of FGS in cancer treatment protocols. Additionally, the demand for minimally invasive procedures is encouraging hospitals to invest in advanced fluorescence-guided laparoscopic and robotic surgery systems. The expansion of AI-assisted surgical planning tools is also influencing market growth, enabling better preoperative mapping of tumors and vascular structures. As surgical technology evolves, fluorescence guided surgery is becoming an indispensable tool for improving patient outcomes.

What’s Driving the Future Growth of the Fluorescence Guided Surgery Systems Market?

The future of FGS is being shaped by AI-enhanced imaging analytics, next-generation fluorescent contrast agents, and the increasing adoption of robotic-assisted surgical platforms. The development of targeted molecular imaging dyes for specific cancers will further improve tumor localization and surgical precision. AI-powered decision support tools will enhance real-time intraoperative guidance, reducing surgical errors and improving resection completeness. Additionally, the expansion of tele-surgical and remote robotic surgery applications will make FGS more accessible in underserved regions. As demand for precision surgery grows, fluorescence guided surgery will continue to redefine modern surgical oncology and neurosurgery.

SCOPE OF STUDY:

The report analyzes the Fluorescence Guided Surgery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (SPY Systems, PDE Systems, VS3 Iridium Systems, Other Types); Surgery (Open Surgery, Laparoscopy / Endoscopy Surgery); Application (Cancer Surgery Application, Cardiovascular Surgery Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â